You are here

Botulinum Toxin Plantibodies

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44AI052590-02A1
Agency Tracking Number: AI052590
Amount: $5,093,490.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: PHS2006-2
Timeline
Solicitation Year: 2006
Award Year: 2006
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
PLANET BIOTECHNOLOGY, INC. 25571 CLAWITER RD
HAYWARD, CA 94545
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 KEITH WYCOFF
 (510) 887-1461
 kwycoff@planetbiotechnology.com
Business Contact
 ELLIOTT FINEMAN
Phone: (510) 887-1461
Email: EFINEMAN@PLANETBIOTECHNOLOGY.COM
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): The ultimate goal of the research described in this application is to develop an economical, safe and effective countermeasure to defend the American public from a bioterrorist attack by botulinum toxin. We aim to be the manufacturer of an antibody or antibody mixture, derived form transgenic plants; that win effectively neutralize botulinum toxin and will supplant the current antitoxin, which is available only in limited supply. We believe that transgenic plants offer the best system for producing high-quality antitoxin at the lowest possible cost. Botulinum toxins (BoNT) are extremely potent neurotoxins produced by anaerobic bacteria of the genus Clostridium. Botulinum neurotoxin A (BoNT/A) is the deadliest biological substance known, with an LD50 between 1-5 ng/kg. Due to their potency and ease of production using unsophisticated techniques, BoNTs have been intentionally produced for use as biological warfare agents and weapons of terror. In Phase I we produced three high-affinity humanized plantibodies against botulinum neurotoxin A (BoNT/A) using transgenic tobacco plants and showed that they are physically very similar to their CHO-cell produced counterparts, that they bind to BoNT/A with similar affinity, and that they protect mice from thousands of LD50s of BoNT/A. We have five aims for Phase II: 1. Produce, in transgenic tobacco, three anti-botox IgG plantibodies with modified Fc sequences to enhance binding to Fc receptors; 2. Examine efficacy, toxicity, and pharmacokinetics of Fc-modified IgG in a mouse model of toxin neutralization; 3. Produce cGMP grade plantibodies for animal and human studies; 4. Examine pharmacokinetics/toxicology of anti-botox IgG plantibodies, and efficacy of toxin neutralization, in a non-human primate model. 5. Examine safety of plant- made antibody in human Phase I clinical trials. Botulinum toxin is the deadliest substance known, and would be easy for a terrorist to produce and use to cause large numbers of casualties. This makes developing an effective and economical countermeasure to protect the public a public health priority. The research supported by this application will lay the groundwork for using plants to produce a highly protective, safe and economical antitoxin therapy.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government